September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Flibanserin, a FDA approved dual serotonin receptor agonist-antagonist, provides retinal neuroprotection from light induced damage
Author Affiliations & Notes
  • Aaron Coyner
    Oregon Health & Science University, Portland, Oregon, United States
  • Renee C Ryals
    Oregon Health & Science University, Portland, Oregon, United States
  • Cristy Ann Ku
    Oregon Health & Science University, Portland, Oregon, United States
  • Rachel C. Patel
    Oregon Health & Science University, Portland, Oregon, United States
  • Cody Fischer
    Oregon Health & Science University, Portland, Oregon, United States
  • Yuquan Wen
    Baylor Visual Function Center, Baylor University Medical Center, Dallas, Texas, United States
  • Rene Hen
    Department of Pharmacology, Columbia University, New York, New York, United States
  • Mark E Pennesi
    Oregon Health & Science University, Portland, Oregon, United States
  • Footnotes
    Commercial Relationships   Aaron Coyner, None; Renee Ryals, None; Cristy Ku, None; Rachel Patel, None; Cody Fischer, None; Yuquan Wen, None; Rene Hen, None; Mark Pennesi, Sucampo (C)
  • Footnotes
    Support  K08 EY021186, Career Development Award from Research to Prevent Blindness (New York, NY), CD-NMT-0914-0659-OHSU, Unrestricted Grant from Research to Prevent Blindness, Casey NIH Core Grant P30 EY 010572
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4397. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Aaron Coyner, Renee C Ryals, Cristy Ann Ku, Rachel C. Patel, Cody Fischer, Yuquan Wen, Rene Hen, Mark E Pennesi; Flibanserin, a FDA approved dual serotonin receptor agonist-antagonist, provides retinal neuroprotection from light induced damage. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4397.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We assessed the neuroprotective effects of Flibanserin (BIMT-17, Addyi), a dual 5-HT1A agonist and 5-HT2A antagonist, in a light-induced retinopathy mouse model.

Methods : Albino BALB/c mice and 5-HT1A KO mice were injected intraperitoneally with either vehicle (to serve as controls) or doses of flibanserin ranging from 0.75 mg/kg to 15 mg/kg. Naïve controls did not receive any injections or light damage. Mice were administered a single injection of flibanserin immediately before light damage or received a five-day treatment course at 48, 24, and 0 hours before light damage and 24 and 48 hours after light damage. Exposing vehicle injected mice to 10,000 lux of uniform light for one hour resulted in light-induced retinopathy. Seven days after light damage, spectral domain optical coherence tomography (SD-OCT) was used to assess retinal structure and electroretinography (ERG) to assess retinal function.

Results : A five-day treatment course of 3 mg/kg, 6 mg/kg, 9 mg/kg and 15 mg/kg flibanserin significantly preserved outer retinal structure and function in a dose dependent manner compared to the vehicle group (p<0.05, ANOVA). A single administration of 15 mg/kg flibanserin completely protected mouse retinas from light-induced retinopathy. Outer retinal thickness and function of the 15 mg/kg flibanserin group were not significantly different from the naïve group (p>0.05, ANOVA). Interestingly, a single 15 mg/kg dose of flibanserin injected immediately prior to light damage completely protected 5-HT1A KO mouse retinas both structurally and functionally from light-induced retinopathy.

Conclusions : Multiple administrations of flibanserin at doses equal to 3 mg/kg or greater can provide partial neuroprotection, while a dose of 15 mg/kg can provide full neuroprotection. Flibanserin is a fast acting drug that can elicit neuroprotection when delivered immediately before light damage. Dosing 5-HT1A KO mice with 15 mg/kg of flibanserin did not lead to a reduction in neuroprotection, suggesting that flibanserin’s neuroprotective effects are not mediated exclusively through 5-HT1A, but potentially through 5-HT2A as well.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×